In the online version of Clinical Cancer Research, a group of investigators from Takeda laboratories address androgen signal transduction in castration-resistant prostate cancer (CRPC). They note that despite castrate levels of testosterone, androgens can be measured in the tissues of patients with CRPC. This is known to result from the conversion of adrenal androgen precursors and de novo androgen biosynthesis in CRPC cells... 
More...
More...